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ABSTRACT: 
The microencapsulation process is used for size reduction with enclosing polymer coat on active pharmaceutical ingredient. The 
microencapsulation process used in present study is solvent evaporation process which formulated prior as o/o emulsification 
process. The polymer for encapsulation was selected based on drug entrapment efficiency and concentration of polymer mix was 
selected in ratio 1:2, further ratio was adjusted in central composite design for application of DOE in which independent variables 
was drug release after 2 hours and permeability across bio membrane after 4 hours. Results are shown revealed significant rise in 
bioavailability of drug than pure API. Scanning electron microscopy referred the size of microcapsule were in range of 10 - 5000 
 m. They were spherical in shape with a rough surface and good solubility. Microcapsule were seen in SEM images are sphere 
with rough surfaces in all batches irrelevant of drug used. Drug encapsulation efficiencies of all the polymes were higher than 
90%, which suggested that this method has potential to prepare microcapsules with efficient drug loading and increased 
bioavailability. 
Keywords: Bioavailability Enhancement, Microencapsulation, Solvent Evaporation Technique, Design of Experiment (DOE), 
Quality by Design (QbD), Central Composite Design. 
 
INTRODUCTION 
In past few decades, biodegradable polymeric 
microcapsules are more focused as their potential in a 
wide range of biomedical applications. 
Microencapsulation is a process by which continuous 
film of polymeric material coated solid, liquid or even 
gaseous particles. These particles are in the size range 
of 1-1000 μm and are widely used as a drug carrier for 
controlled release. Poly Vinyl Pyrolidon are common 
and cheap biopolymers used in industry vastly as film 
forming agent to carry water-insoluble model drugs. 
Pyrolidones-based microcapsules of PVPK-30 
1, 2, 3
, 
soluplus
4,5 
have been used as biodegradable layer for 
fast release drugs. Solvent evaporation techniques have 
become more useful method as compared to other 
methods. The particle size can be controlled in the 
nano to micrometer range can be possible by this 
method, but importance of careful selection of 
encapsulation materials and various conditions in order 
to achieve high encapsulation efficiency and a low 
residual solvent content should not be neglected. 
Solvent evaporation method
6
 is investigated for 
preparing the Pyrolidones-based microcapsules as drug 
entrapment efficiency is high in this method. 
Microspheres are formulated so as to maintain the 
concentration of drug in blood constantly and increase 
patient compliance, decrease dose and toxicity and the 
taste and odour of many drugs can be masked, liquid 
drugs can be converted into a free flowing powder, 
incompatibility among the drugs can be prevented 
7
.  
The statistical approach leads to prepare microcapsule 
with higher efficiency with higher throughput. The 
design Expert 9.0 used for development of 
microcapsule and desirability of final optimised batch 
can be evaluated with the help of contour and surface 
response plot suggested by design expert. Microsphere 
preparation by solvent extraction/ evaporation basically 
consists of four major steps:(i) dissolution or dispersion 
of the bioactive compound often in an organic solvent 
containing the matrix forming material; (ii) 
emulsification of this organic phase in a second 
continuous phase immiscible with the first one; (iii) 
extraction of the solvent from the dispersed phase by 
the continuous phase, which is optionally accompanied 
by solvent evaporation, either one transforming the 
droplets into solid microspheres; (iv) harvesting and 
drying of the microspheres
8
. 
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MATERIALS 
Polyvinyl pyrolidones K30, Soluplus, Cefuroxime 
Axetil were purchased from Swapnroop Drugs, 
Aurangabad by Store department of Anuradha College 
of Pharmacy Chikhli. 
METHODOLOGY 
Preformulation studies 
Standard Calibration Curve 
Standerd Calibration Curve of Cefuroxime Axetil 
prepared in 7.0 pH phosphate buffer at λmax280 nm. 
Standard Calibration Curve of Cefpodoxime Proxetil 
was prepared in 3.0 pH phosphate buffer at λ max 233 
nm. Standard Calibration Curve of Furosemide was 
prepared in 5.8 pH phosphate buffer at λmax 274 nm 
using Shimadzu 1601 UV-Visible spectrophotometer.  
For this stock solution of 1000µg/ml was prepared. 
Serial dilutions of 10, 20, 30, 40 µg/ml were prepared 
and absorbance was taken. Average of three sets of 
values were taken for standard calibration curve and 
solutions were scanned in the range of 200-400 nm 
against blank. The calibration curve was plotted. The 
preformulation studies carried out with the help of IR 
spectrophotometer and DSC study is carried out to 
study the thermal stability of the drug with presence of 
the different excipients
9
. 
FTIR Study 
The FTIR study was performed for evaluation of drug 
and API interaction which was further studied with the 
Help of FTIR spectra arise with the any unusual graph 
pattern which was compared with standard spectra. 
DSC Study 
The DSC study was performed to get the idea of the 
interaction of drug and polymer in higher temperature 
and its affect at inert environment. The effect of the 
drug and polymer after microencapsulation process 
studied with DSC study. 
Saturated Solubility Study 
Saturated solubility study performed to evaluate the 
drug entrapment capacity of the polymer of drug. The 
microcapsule prepared with various concentration i.e 
1:0.3, 1:0.5, 1:1, 1:2 by drug: polymer ratio 
respectively. The saturated solubility of each individual 
microcapsule studied by taking specified amount in 
glass vial containing water which rotated on lab shaker 
for 24 hours. The sample were prepared and diluted 
further for analysing drug contained in it 
7,8,9,11
. 
Polymer Selection with Response Surface 
Methodology (RSM) 
The polymer blend selected for preparation of 
microcapsule regarding the desired quality to be 
achieved after formulation of microcapsule such as 
drug solubility which leads to enhance drug dissolution 
and drug permeability which was evaluated with the 
help of in vitro methods. The polymer blend selected 
with the help of RSM statistical method with central 
composite design using Design Expert 9.0 (Trial 
Version). The polymer blend i.e fixed variables are X1 
is PVPK 30 and X2 is Soluplus. While the responses 
are Drug release (Q 2 i.e. after 2 hours) and 
Permeability after 4 hours. 
Table 1: Coded Value of Polymer (Fixed Variables) 
Sr. No. Fixed Variables Coded Value 
1 PVPK 30 X1 
2 Soluplus X2 
 
Preparation of Microcapsules 
The microcapsules prepared with help of solvent 
evaporation method in this the pre-weighed and pre-
mixed polymer blend mixed in acetone to form a clear 
solution. In another beaker containing 250 ml liquid 
paraffin with 0.1% Tween 80. The Drug suspended in 
liquid paraffin with help of magnetic stirrer. While 
continuing stirring clear solution of polymer blend in 
acetone added drop wise into liquid paraffin containing 
drug. The solution continued to stir on magnetic stirrer 
to evaporate acetone from the system at room 
temperature for 2-3 hours. 
After stirring microcapsules are decanted and filtered. 
The microcapsules are washed severally with n-hexane 
to remove residual liquid paraffin. The final 
microcapsules are stored in tightly closed container for 
further development of dosage form 
11,2
. 
Characterization of Microcapsules 
SEM Analysis 
Surface Morphology of the microcapsule was 
investigated by scanning electron microscopy (SEM) 
using a JEOL JSM-6510 SEM. The microspheres were 
coated with gold before scanning to enhance their 
conductivity. The surface morphology can reveals by 
SEM image also the coated core material enclosed with 
coating polymer can be inferred. 
Drug Entrapment Efficiency 
Drug content which entrapped by polymers of the 
microcapsules were determined by UV-vis 
spectrophotometry. The microcapsule equivalent to 50 
mg drug were dissolved in acetone 2ml and diluted 
with buffer solution. A clear solution was obtained for 
drug content measurement. Drug content values were 
the average from three experiments.  
In vitro drug release study 
The drug release profile was carried out with the help 
of drug dissolution apparatus Type 1 (Basket type). 
The microcapsule of single dose quantity filled in 
basket and rotated in dissolution flask containing buffer 
with temperature maintained at 37 ± 0.5°C for 2 hours. 
After specific time period the 2ml aliquote withdrawn 
from dissolution flask and exactly same quantity of 
same temperature buffer added in the flask to maintain 
sink condition. The aliquots were further diluted and 
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analysed. The release profile of the drug carried out in 
triplicate 
5
. 
In Vitro Drug Permeability study 
The drug permeability study includes the study of the 
drug formulation and its effect on the drug 
permeability through intestinal membrane. The vitro 
model selected for studying in vitro permeability of the 
drug was modified Wilson and crane apparatus for 
drug permeability measurement. In this study the 
everted gut sac of chicken illieum tied with glass tube 
which made pouch like structure open at one end with 
tied knot at other. Filled with buffer then dipped in 
bottle containing drug solution and aerated the whole 
system as well as maintained at 37 ±0.5° C 
13
. 
The samples are withdrawn after specific time period 
from the attached tube of the gut section and filled with 
exactly same amount of fresh buffer added in it to 
maintain sink condition. The samples were further 
diluted and analysed. The samples were analysed 
triplicate by UV spectrophotometric analysis 
4
. 
RESULT AND DISCUSSION 
The microcapsules prepared by this method were 
discrete and individual system with free flowing nature 
having nearly uniform size. 
Preformulation Study 
Standard Calibration Curve 
The drug evaluated for formulation before their 
formulation. The absorbance maxima of the individual 
drug determined with their respective buffer solutions.  
Standard Calibration Curve of Cefuroxime Axetil was 
prepared in 7.0 pH phosphate buffer at λmax 280 nm. 
Standard Calibration Curve of Cefpodoxime Proxetil was 
prepared in 3.0 pH phosphate buffer at λmax 
233nm.Standerd Calibration Curve of Furosemide was 
prepared in 5.8 pH phosphate buffer λmax 274nm. Using 
UV-Visible spectrophotometer. For this stock solution of 
1000 µg/ml was prepared. Serial dilutions of 5, 10, 15, 20, 
25 µg/ml were prepared and absorbance was taken. 
Averages of 3 sets of values were taken for standard 
calibration curve, and solutions were scanned in the range 
200-400 nm against blank. The calibration curve was 
plotted. 
 
 
Figure 1: Absorbance Maxima of Cefuroxime Axetil at 
280 nm 
 
Figure 2: Absorbance maxima of Cefpodoxime 
Proxetil at 233 nm 
 
Figure 3: Absorbance maxima of Furosemide at 274 
nm 
Standard Calibration Curve of Cefuroxime Axetil 
 
Figure 4: Standard Calibration Curve of Cefuroxime 
Axetil 
Standard Calibration Curve of Cefpodoxime 
Proxetil 
 
Figure 5: Standard Calibration Curve of Cefpodoxime 
Proxetil 
Standard Calibration Curve of Furosemide 
 
Figure 6: Standard Calibration Curve of Furosemide
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Fourier Transformed Infra Red Spectrophotometer 
 
Figure 7: Cefuroxime Axetil Microcapsules overlay Graph 
The IR spectra of microcapsule having the same content 
as that of solid dispersion and showing exactly same 
graphs a formulation process not make any significant 
changes in structure of the drug in functional group 
hence indicating no interaction between drug and 
ingredients in microcapsules.  
 
 
Figure 8: Overlay Spectctra of Cefpodoxime Proxetil and Microcapsules 
The IR spectra of microcapsule having the same content 
as that of solid dispersion and showing exactly same 
graphs and formulation process not make any 
significant changes in structure of the drug in functional 
group hence indicating no interaction between drug and 
ingredients in microcapsules.  
 
The IR spectra of microcapsule having the same content 
as that of solid dispersion and showing exactly same 
graphs a formulation process not make any significant 
changes in structure of the drug in functional group 
hence indicating no interaction between drug and 
ingredients in microcapsules. 
 
Figure 9: Overlay spectra of Furosemide and Microcapsules 
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DSC Study 
The DSC Graphs shows endothermic curve on 
88.80°C. Also exothermic peak shows on 252°C (Fig. 
74) for pure cefuroxime axetil. The microcapsule 
shows transition temperature 217.24°C which shows 
complete impingement of drug core inside carrier of 
polymers as shown in SEM image. 
 
Figure 10: DSC of Cefuroxime Axetil 
 
Figure 11: DSC of Microcapsule Cefuroxime Axetil 
 
Figure 12: DSC of Cefpodoxime Proxetil 
 
Figure 13: DSC of Microcapsule Cefpodoxime Proxetil 
The DSC Graphs shows sharp endothermic curve on 
222.95°C and 275.94°C. Exothermic curve on 224.19°C, 
resulting in showing the crystalline nature of drug. The 
microencapsulated furosemide shows transition 
temperature 227.24°C resulting in no change of drug 
nature and concludes complete impingement of drug in 
polymer matrix. 
 
Figure 14: DSC of Furosemide 
 
Figure 15: DSC of Microcapsule Furosemide 
Saturated Solubility Study 
The solution gives the drug content as follows 
 
Figure 16: Saturated Solubility Study of PVPK 30 
and Cefuroxime Axetil 
 
Figure 17: Saturated Solubility Study of Soluplus 
and Cefuroxime Axetil 
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Figure 18: Saturated Solubility Study of PVPK 30 
 
Figure 19: Saturated Solubility Study of Soluplus 
and Cefpodoxime Proxetil 
 
Figure 20: Saturated Solubility Study of PVPK 30 
and Furosemide 
 
Figure 21: Saturated solubility study of Soluplus 
and Furosemide 
From above graph it can be suggested that amount of 
PVPK is more favourable for improvement of 
solubility and microencapsulation formation hence the 
polymer concentration was decided as 1:2 for Soluplus 
and PVPK respectively. 
Formulation by Central Composite Design 
The Design expert software 9.0 were used for 
determination of polymer concentration to be taken 
while formulation. Ratio of soluplus and PVPK kept at 
1:2 respectively. The formulation decided with the help 
of results obtained from saturated solubility study of 
PVPK, Soluplus, and drug in respective Buffer. The 
formulation trials are as follows; 
 
Table 2: Batch Ingredient Concentration Taken 
Variable 
Code 
-1 0 +1 Ingrediant 
X1 283.33 333.33 383.33 PVPK 30 
X2 141.33 166.66 191.33 Soluplus 
 500 Drug 
 
Table 3: Batch Formula Codes 
Variable 
Code 
Batches Formulated 
X1 -1 0 +1 
X2 -1 0 +1 
 
Table 4: Final Formulation Runs 
Run Factor1: PVPK Factor2: Soluplus 
1 0 -1 
2 0 1 
3 -1 1 
4 1 1 
5 1 -1 
6 -1 0 
7 -1 -1 
8 1 0 
9 0 0 
 
The Batches are formulated according to the formula 
shown in table 2 for determination of bioavailability of 
the formulation. The microcapsules prepared by the 
above batches evaluated for drug release study and 
permeability study. 
Characterization of Microspheres 
Scanning Electron Microscopy (SEM) 
The SEM of drug performed and shows the distorted 
and irregular, rough shaped crystals of the drug having 
nonspecific size crystals with rough surface. In the 
SEM photograph of cefuroxime axetil after 
microencapsulation shows a small bead like structure 
with layer of coating polymer upon it leads to the 
conclusion of proper coating of small core of drug with 
polymer. 
 
Figure 22: SEM of Cefuroxime Axetil 
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Figure 23: SEM of Microcapsule 
Cefuroxime Axetil 
 
Figure 24: SEM of Cefpodoxime 
Proxetil 
 
Figure 25: SEM of Microcapsule of 
Cefpodoxime Proxetil
 
 
Figure 26: SEM of Furosemide 
 
Figure 27: SEM of Microcapsule 
furosemide 
Drug Entrapment Efficiency 
The Drug entrapment study 
performed prior to drug release 
study for evaluating the drug 
loaded in the formulation in 
right proportion as well as the 
efficiency of process for drug 
entrapment for study release 
profile study evaluated for its 
release pattern with errors.
 
Table 5: Actual Drug Content 
Sr. No. PVPK SOLUPLUS 
Drug Entrapment Efficiency (%) 
Cefuroxime 
Axetil 
Cefpodoxime 
proxetil 
Furosemide 
1 0 -1 99.86±0.690 96.94±0.744 98.87± 0.656 
2 0 1 95.07±0.802 99.33±0.602 99.36±0.603 
3 -1 1 100.51±1.120 99.87±0.654 100.30±0.576 
4 1 1 98.43±0.704 100.04±0.681 97.57±0.705 
5 1 -1 99.22±1.054 99.38±0.528 99.1±0.552 
6 -1 0 95.69±1.045 97.48±0.55 100.34±0.412 
7 -1 -1 99.36±1.238 99.73±.1.1 100.98±0.659 
8 1 0 96.29±1.075 97.42±0.315 97.16±0.431 
9 0 0 97.37±1.193 99.41±1.304 98.29±0.690 
All values are expressed as mean±SD, (number of terms) n=3 
The in vitro drug release profile shown by the coded batch as follows 
Table 6: Characteristics of Cefuroxime Axetil Microcapsules 
Batch 
Run 
X1 X2 Dissolution (%) after 2 hrs Permeability (mg/ml) 
1 0 -1 53.63 ± 0.0154 1.859 ±0.0133 
2 0 1 55.88 ± 0.0131 2.952 ± 0.0116 
3 -1 1 41.14 ± 0.0149 3.224 ± 0.0047 
4 1 1 66.48 ± 0.0295 3.882 ± 0.0322 
5 1 -1 69.63 ± 0.0406 2.291 ± 0.0249 
6 -1 0 45.29 ± 0.2165 2.573 ± 0.01083 
7 -1 -1 37.65 ± 0.0482 1.433 ± 0.01049 
8 1 0 62.45 ± 0.0384 2.774 ± 0.01214 
9 0 0 58.39 ± 0.0543 2.711 ± 0.01655 
All values are expressed as mean±SD, (number of terms) n=3 
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Effect on Indpendant Variables: 
Table 7: ANOVA of independent variables 
Dependent 
variables 
Source of variation 
Sum of 
squares 
Degree of 
freedom 
F value 
P 
value Source 
 
Std. 
Deviation 
R-
Square 
Predicted 
R-Square 
Dissolution (T2) Linear 3.54 0.9250 0.8283 925.66 2 37.02 
0.0004 
 
Permeability Linear 0.25 0.9124 0.7995 3.83 2 31.24 0.0007 
 
Final Equation in Terms of Coded Factors: 
The model proposes the following polynomial equation for percentage drug entrapment (Cefuroxime Axetil) by 
Polymer 
Dissolution (Y) = 54.504 + 12.41X1 + 0.431X2  
Permeability = 2.63+0.29X1+0.75X2
 
 
Figure 28: RSM plot for Effect on Dissolution by individual polymer Cefuroxime Axetil 
 
From above RSM plot shows that the solubility of drug depends on the concentration of both polymers as 
concentration of polymer rises the solubility also increases but if compared individual polymer then it concluded that 
the PVPK 30 is more responsible to enhance the solubility of the drug. 
 
Figure 29: RSM plot for Effect on Permeability by individual polymer Cefuroxime Axetil. 
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From above RSM plot shows that the permeability of drug depends on the concentration of Soluplus while PVPK 30 
doesn’t play any significant role in permeability enhancement 
Desirability plot for polymer for bioavailability enhancement: 
The desirability plot shows the most desirable concentration of the batch runs to achieve most efficient bioavailability 
with significant economical and efficient method. 
 
Figure 30: Desirability plot for polymer use Cefuroxime Axetil 
The in vitro drug release profile shown by the coded batch as follows 
Table 8: Characteristics of Cefpodoxime Proxetil Microcapsules 
Batch 
Run 
X1 X2 Dissolution (%) after 2 hrs Permeability (mg/ml) 
1 0 -1 53.03±0.269 2.044 ± 0.0115 
2 0 1 53.48±0.0252 3.187 ± 0.025 
3 -1 1 43.1±0.0325 3.475 ± 0.039 
4 1 1 65.36±0.0451 4.267 ± 0.045 
5 1 -1 73.8±0.307 2.376 ± 0.008 
6 -1 0 44.89±0.120 2.742 ± 0.008 
7 -1 -1 39.35±0.043 1.615 ± 0.018 
8 1 0 63.0±0.188 2.930 ± 0.012 
9 0 0 60.18±0.037 2.911 ± 0.0149 
All values are expressed as mean±SD, (number of terms) n=3 
Effect on Independent valuables 
Table 9: ANOVA of independent variables 
Dependent 
variables 
Source of variation 
Sum of 
squares 
Degree 
of 
freedom 
F value 
P 
value Source 
 
Std. 
Deviation 
R-
Square 
Predicted 
R-Square 
Dissolution 
(T2) 
Linear 4.29 0.8945 0.7505 936.00 2 25.44 0.0012 
Permeability Linear 0.27 0.9118 0.7955 4.50 2 31.00 0.0007 
 
Final Equation in Terms of Coded Factors 
The model proposes the following polynomial equation for percentage drug entrapment (Cefpodoxime Proxetil) by 
Polymer. 
Dissolution ( Y ) = 54.504 + 12.41X1 + 0.431X2 
Permeability = 2.63+0.29X1+0.75X2 
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Figure 31: RSM plot for Effect on Dissolution by individual polymer Cefpodoxime Proxetil 
 
From above RSM plot shows that the solubility of drug depends on the concentration of both polymers as 
concentration of polymer rises the solubility also increases but if compared individual polymer then it concluded that 
the PVPK 30 is more responsible to enhance the solubility of the drug. 
 
Figure 32: RSM plot for Effect on Permeability by individual polymer Cefpodoxime Proxetil. 
From above RSM plot shows that the permeability of drug depends on the concentration of Soluplus while PVPK 30 
doesn’t play any significant role in permeability enhancement. 
Desirability plot for polymer for bioavailability enhancement 
The desirability plot shows the most desirable concentration of the batch runs to achive most efficient bioavailability 
with significant economical and efficient method. 
 
Figure 33: Desirability plot for polymer use Cefpodoxime Proxetil 
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Table 10: Characteristics of Furosemide Microcapsules 
Batch Run X1 X2 Dissolution (%) after 2 hrs Permeability (mg/ml) 
1 0 -1 41.91± 0.029 1.64 ± 0.0115 
2 0 1 45.67± 0.029 2.743 ± 0.0110 
3 -1 1 28.75±0.020 3.061 ± 0.0086 
4 1 1 57.37±0.009 3.554 ± 0.010 
5 1 -1 63.01±0.018 1.946 ± 0.008 
6 -1 0 33.13±0.022 2.067 ± 0.008 
7 -1 -1 24.37±0.022 1.115 ± 0.003 
8 1 0 54.25±0.015 2.368 ± 0.006 
9 0 0 50.5±0.016 2.397 ± 0.007 
All values are expressed as mean±SD, (number of terms) n=3 
 
Effect on Independent Variables 
Table 11: ANOVA of independent variables 
Dependent 
variables 
Source of variation 
Sum of 
squares 
Degree of 
freedom 
F 
value 
P 
value Source 
 
Std. 
Deviation 
R-
Square 
Predicted 
R-Square 
Dissolution 
(T2) 
Linear 4.60 0.9113 0.8026 1302.88 2 30.82 0.0007 
Permeability Linear 0.23 0.9263 0.8198 4.05 2 37.71 0.0004 
 
Final Equation in Terms of Coded Factors 
The model proposes the following polynomial equation for percentage drug entrapment (Furosemide) by Polymer 
Dissolution (Y) = 54.504 + 12.41X1 + 0.431X2 
Permeability = 2.63+0.29X1+0.75X2
2 
 
 
Figure 34: RSM plot for Effect on Dissolution by individual polymer Furosemide 
 
From above RSM plot shows that the solubility of drug depends on the concentration of both polymers as 
concentration of polymer rises the solubility also increases but if compared individual polymer then it concluded that 
the PVPK 30 is more responsible to enhance the solubility of the drug. 
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Figure 35: RSM plot for Effect on Permeability by individual polymer Furosemide 
 
From above RSM plot shows that the permeability of drug depends on the concentration of Soluplus while PVPK 30 
doesn’t play any significant role in permeability enhancement 
Desirability plot for polymer for bioavailability enhancement 
The desirability plot shows the most desirable concentration of the batch runs to achive most efficient bioavailability 
with significant economical and efficient method. 
 
 
Figure 36: Desirability plot for polymer use Furosemide 
The in vitro drug release profile shown by the coded batch as follows 
Table 12: In Vitro Drug Release Profile 
Time (min) CA CP Fur CA (1   1) CP (1   1) Fur (1   1) 
0 0 0 0 0 0 0 
10 0.0034± 0.0276 0.0048± 0.0088 0.0576± 0.0091 16.978± 0.199 18.486± 0.243 13.434± 0.183 
20 0.0077± 0.0545 0.0083± 0.010 0.0721± 0.0096 24.983± 0.723 26.273± 0.614 19.978± 0.161 
30 0.0115± 0.0373 0.0126± 0.140 0.0858± 0.0215 38.218± 1.017 39.263± 0.470 32.344± 0.324 
60 0.0279± 0.0355 0.0294± 0.110 0.1143± 0.0135 54.9876± 0.623 56.98± 1.530 46.478± 0.395 
90 0.0529± 0.150 0.0683± 0.104 0.1722± 0.0640 60.353± 1.576 63.91± 0.454 53.394± 0.424 
120 0.067± 0.110 0.0893± 0.154 0.1903± 0.0468 66.484± 1.738 65.361± 0.520 57.378± 0.096 
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CONCLUSIONS 
The solvent evaporation method is very much useful in 
obtaining the encapsulation of water insoluble drug 
coated with water soluble polymer blend with high 
throughput by statistical method central composite 
design. For the solvent evaporation method, the polymers 
blend was selected depending on encapsulation 
efficiency of the polymer to be used in 
microencapsulation. In this system the acetone 
solubilised polymer blend and liquid paraffin forms a 
primary emulsion with the help of 0.1% of tween 80. The 
microcapsules form due to coating of polymer blend 
after evaporation from the organic solvent onto the core 
suspended in oil phase.  The polymer blend prepared as 
per microencapsulation efficiency of polymer as well as 
drug release study and permeability study. The 
microencapsulation can be effective in bioavailability 
enhancement due to its micron size range and coating of 
individual particles effective in drug dissolution. 
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